Clinical trials: Osimertinib
Non Small Cell Lung Cancer, EGFR Gene Mutation
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
This study is a single-center, prospective, single-arm study of the efficacy of double-dose Furmonertinib in the treatment of patients with slow Osimertinib-resistant non-small cell lung cancer, mainly in patients with advanced…
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non-small Cell Lung Cancer Stage IV
- Trial name
- NCT06117644
- Testing
- Furmonertinib
- Volunteers
- 30 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
The goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA/AKT1/PTEN alterations after progression on first-line…
- Conditions
- Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer
- Trial name
- Precision (NCT07486648)
- Testing
- Capivasertib in combination with Osimertinib
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Shanxi Province Cancer Hospital
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03191149
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
- Where
- 347 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced…
- Trial name
- NCT02099058
- Testing
- Osimertinib, Nivolumab, Telisotuzumab vedotin
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 237 people
- Sponsor
- AbbVie
Locally Advanced or Metastatic NSCLC
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.
- Trial name
- NCT03414814
- Testing
- Osimertinib 80 MG [Tagrisso]
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Seoul National University Hospital
Advanced Non-small Cell Lung Cancer
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
This is a nonrandomized, open phase I dose escalation and extension clinical study designed to evaluate Aurora A inhibitor VIC-1911 tablets in combination with oxitinib in Chinese patients with advanced non-small cell lung cancer…
- Trial name
- VIC-1911 (NCT05489731)
- Testing
- VIC-1911, Osimertinib Mesylate Tablets
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
MRD
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer…
- Trial name
- NCT05536505
- Testing
- Adjuvant treatment for MRD positivity
- Where
- 16 sites in China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have…
- Conditions
- Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer NSCLC, Non Small Cell Lung Carcinoma
- Trial name
- OMAE (NCT07563205)
- Where
- 16 sites in France
- Volunteers
- 100 people
- Sponsor
- GFPC Investigation
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
The goal of this observational study is to extract the imaging features of brain lesions and primary lung lesions in NSCLC patients with brain metastases by deep learning, as well as common clinicopathological parameters, which…
- Trial name
- NCT06604689
- Testing
- third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Fudan University
Leptomeningeal Metastasis
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis
- Trial name
- NCT04356118
- Testing
- Recombinant Human Endostatin, intrathcal methotrexate, Targeted drugs for non-small cell lung cancer
- Volunteers
- 30 people
- Sponsor
- Hui Bu
Non Small Cell Lung Cancer, EGFR Gene Mutation
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation
- Trial name
- PIKACHU (NCT04322890)
- Testing
- Osimertinib, Alectinib 150 MG, Crizotinib 250 MG
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
This is a single-center, open-label, phase I clinical trial aimed to evaluate the efficacy and safety of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small…
- Trial name
- NCT05507606
- Testing
- Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
This is a prospective, biomarker-driven, open-label, clinical trial of osimertinib in treatment- naïve patients with EGFR mutant NSCLC, to evaluate the efficacy of osimertinib according to the TP53 mutational status.
- Trial name
- TEMPLE-2 (NCT05785208)
- Testing
- Osimertinib
- Where
- 11 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Carcinoma, Non-Small-Cell Lung
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy and safety of osimertinib with or without savolitinib as first-line therapy in patients with de novo MET positive, EGFR-mutant advanced…
- Trial name
- FLOWERS (NCT05163249)
- Testing
- Osimertinib, Savolitinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Cancer
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.
- Trial name
- NCT03891615
- Testing
- Niraparib, Osimertinib
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer
Personalized DC Vaccines in Non Small Cell Lung Cancer
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard of care (SOC) therapy in patients with advanced or…
- Trial name
- NCT05195619
- Testing
- Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine), Low dose cyclophosphamide
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Leptomeningeal Metastasis, Non-small Cell Lung Cancer
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) associated with poor prognosis and rapid deterioration of performance status.
- Conditions
- Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation
- Trial name
- OWBLM (NCT04425681)
- Testing
- Osimertinib, Bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non-small Cell Lung Cancer
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Lung cancer (LC) is the tumor responsible for the highest mortality worldwide. Lung adenocarcinoma is the major subtype of lung cancer and represents the deadliest human cancer, affecting current-, ex-, and even non-smokers.
- Trial name
- OSIREAL (NCT06068049)
- Where
- 26 sites in Spain
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Lung Neoplasms, Non-Small Cell Lung Cancer
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer
Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation.
- Trial name
- PTR-2 (NCT07738172)
- Testing
- Primary Tumor Resection, Osimertinib
- Where
- Taiwan
- Volunteers
- 154 people
- Sponsor
- National Taiwan University Hospital
EGFR Positive Non-small Cell Lung Cancer, MET Amplification
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Osimertinib combined with savolitinib in the treatment of EGFR mutated osimertinib resistant NSCLC with low copy number MET amplification There are unmet medical needs in patients who resist to to osimertinib; savolitinib plus…
- Trial name
- NCT07322783
- Testing
- • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qingdao Central Hospital